which thousands of unmodified transposons may have been recruited for their transposase as part of the catalytic machinery of RNA-guided genome rearrangements just before they are eliminated from the macronuclear genome. In support of this model, we found that IES excision can precede transposon elimination ( fig. S6 ), refuting a simple indirect effect of genome rearrangements occurring only after transposon processing. Transient TBE transposase expression begins after meiosis ( Fig. 1 and fig. S1 ) and coincides with the production of maternal RNA templates that guide rearrangement (5) as well as all events of DNA processing, including TBE transposon elimination, IES excision, and segment-reordering in the developing nucleus (22) . 
MAPK3/1 (ERK1/2) in Ovarian Granulosa Cells Are Essential for Female Fertility
Heng-Yu Fan, 1 Zhilin Liu, 1 Masayuki Shimada, 2 Esta Sterneck, 3 Peter F. Johnson, 4 Stephen M. Hedrick, 5 JoAnne S. Richards 1 * A surge of luteinizing hormone (LH) from the pituitary gland triggers ovulation, oocyte maturation, and luteinization for successful reproduction in mammals. Because the signaling molecules RAS and ERK1/2 (extracellular signal-regulated kinases 1 and 2) are activated by an LH surge in granulosa cells of preovulatory follicles, we disrupted Erk1/2 in mouse granulosa cells and provide in vivo evidence that these kinases are necessary for LH-induced oocyte resumption of meiosis, ovulation, and luteinization. In addition, biochemical analyses and selected disruption of the Cebpb gene in granulosa cells demonstrate that C/EBPb (CCAAT/Enhancer-binding protein-b) is a critical downstream mediator of ERK1/2 activation. Thus, ERK1/2 and C/EBPb constitute an in vivo LH-regulated signaling pathway that controls ovulation-and luteinization-related events. I n the mammalian ovary, the female germ cells (oocytes) reside within the ovarian follicles and are surrounded by somatic cell-derived granulosa cells (GCs) and cumulus cells that have endocrine functions and control oocyte maturation. Female reproductive success depends on the growth of ovarian follicles and differentiation of GCs as well as oocyte matura-tion and ovulation (1, 2) . Although LH plays a critical role in the initiation of ovulation and in the terminal differentiation of GCs to luteal cells that compose the corpora lutea (CLs) and produce progesterone, the precise molecular targets in these processes remain ill-defined. Cyclic adenosine 3´,5´-monophosphate (cAMP) is a well-known mediator of LH action, but LH also induces expression of the epidermal growth factor (EGF)-like factors that, via activation of the EGF receptor, RAS, and extracellular signalregulated kinases 1 and 2 [ERK1/2, also known as mitogen-activated protein kinases 3 and 1 (MAPK3/1)], may act as the intrafollicular mediators to stimulate the cumulus cell-oocyte complex (COC) expansion and oocyte maturation (3) (4) (5) . However, specific role(s) of the EGF network and, more specifically, of ERK1/2 in regulating ovulation, oocyte maturation, and the global reprogramming of GCs to luteal cells have not yet been analyzed or defined clearly in vivo.
ERK1 and ERK2 are coexpressed in all mammalian tissues and implicated as key regulators of cell proliferation and differentiation as well as oocyte maturation in culture (6, 7) . Mutant mouse models have shown that Erk1-null mice are viable and fertile (8) , but mutation of the Erk2 gene is embryonic lethal in mice (9) . To analyze the specific ovarian functions of ERK1 and ERK2 in vivo, we crossed Erk2 fl/fl mice (10) with the Cyp19-Cre transgenic mice (11) , and the resultant Erk2 fl/fl ;Cyp19-Cre mice were further crossed into the Erk1 −/− background (8), yielding Erk1 −/− ;Erk2 fl/fl ;Cyp19-Cre (Erk1/2 gc−/− ) mice. Efficient depletion of ERK1 and/or ERK2 in the mutant GCs and cumulus cells, as well as the lack of phosphorylation of ERK1/2 in the mutant GCs in vivo, was demonstrated (fig. S1, A to C). Loss of ERK1/2 did not impair LH-mediated activation of known upstream regulators of ERK1/2 or other LH-regulated signaling molecules (fig. S1, D and E) but did block phosphorylation of the ERK1/2 target RPS6KA2 (P90RSK) ( fig. S1D ).
The Erk1 −/− and Erk2 gc−/− females were fertile; however, the Erk1/2 gc−/− females failed to ovulate and were completely infertile ( Fig. 1A ). Specific analyses of oocyte functions showed that oocytes isolated from the COCs of Erk1/2 gc−/− mutant mice spontaneously underwent GVBD in culture and progressed to metaphase II stage, as did controls ( fig. S3A ). By contrast, when spontaneous GVBD was blocked by hypothanxine (HX), the EGF-like factor amphiregulin (AREG) stimulated GVBD in wild-type (WT) but not Erk1/2 gc−/− COCs ( fig. S3B ). In addition, AREG stimulated expansion of COCs isolated from WT, but not the Erk1/2 gc−/− mice ( fig. S3C ). These results indicate that the oocytes that retain ERK1/2 in the Erk1/2 gc−/− mice are competent for meiotic maturation, but the cumulus cells lacking ERK1/2 (fig. S1B) fail to respond to EGF-like factors.
Ovaries of adult
Furthermore, the ability of LH/hCG (human chorionic gonadotropin) to terminate GC proliferation was impaired in the Erk1/2 gc−/− mice, as indicated by elevated incorporation of bromodeoxyuridine (BrdU) (Fig. 2, A To identify ERK1/2 target genes in preovulatory follicles, we analyzed gene expression profiles using RNA prepared from GCs obtained from WT and Erk1/2 gc−/− mice treated with eCG for 48 hours and at 0, 2.5, and 4 hours after hCG injection because the activation of ERK1/2 peaks at 2 hours after hCG treatment (11, 12) and many genes that affect ovulation are maximally expressed by 4 hours (5). Among the 563 highly regulated LH target genes (more than fourfold, hCG at 4 hours versus hCG at 0 hours; 466 with increased and 97 with decreased expression, tables S1 and S2), 77% (376 with increased and 57 with decreased expression) lost their response to LH/hCG in the Erk1/2 gc−/− cells (Fig. 3A) . Two identified ERK1/2 target genes that regulate estradiol biosynthesis and activity are Cyp19a1 (aromatase), which converts testosterone to estradiol, and Sult1e1, which deactivates estradiol (13) . Whereas hCG turns off Cyp19a1 expression in WT mice, Cyp19a1 was markedly increased in the Erk1/2 gc−/− cells. By contrast, hCG transiently induced Sult1e1 in WT but not Erk1/2 −/− GCs ( Fig. 3B and tables S1 and S2), leading to inappropriately high estradiol concentrations ( Fig. 1F and fig. S2B ) that may adversely affect the ovary and other tissues as well (13) . Conversely, two luteinization markers, Star and Cyp11a1, were substantially reduced in the Erk1/2 gc−/− ovaries, consistent with the lack of CLs in the mutant mice ( Fig. 2, C to F, and fig.  S5, A and B ).
The expression of many genes associated with COC expansion and ovulation (Ptgs2, Tnfaip6, Has2, Ptx3, and Pgr) was abolished in the Erk1/2 gc−/− ovaries, as indicated by the microarray data (table S1), quantitative reverse transcription-polymerase chain reaction (qRT-PCR) ( Fig. 3C and fig. S5A ), and immunoflu-orescence ( fig. S5D ), whereas genes encoding the two EGF-like factors Areg and Ereg, presumed mediators of LH action, were induced rapidly to normal (Ereg) or reduced (Areg) levels compared to controls but these levels were not sustained. By contrast, the induction of betacellulin (Btc) was blocked completely in Erk1/2 gc−/− ovaries (Fig. 3D) . Thus, the initial induction of Areg and Ereg by LH/hCG is largely independent of ERK1/2 activation. However, the induction of Btc and the secondary maintenance of Areg and Ereg expression is likely dependent on ERK1/2 induction of Ptgs2, leading to prostaglandin E2 (PGE2) production and activation of the EP2 receptor (5) .
By contrast, genes in addition to Cyp19a1 that are expressed and/or induced by folliclestimulating hormone (FSH) and equine chorionic gonadotropin (eCG) in GCs during preovulatory follicle development (Fshr, Lhcgr, and Nr5a2) ( fig. S6 ) and normally down-regulated during the early stages of LH-induced luteinization (14) were expressed at elevated levels in ovaries of the hormone-treated Erk1/2 gc−/− mice ( Fig. 3B and fig. S5C ). Thus, ERK1/2 is required for suppressing the expression of FSH target genes.
Mice null for the transcription factor CCAAT/ Enhancer-binding protein-b (Cebpb) are one of a only few knockout mouse models that show an Erk1/2 gc−/− -like ovarian phenotype (15) . C/EBPb protein is increased rapidly by hCG in GCs in vivo ( fig. S7, A and B) , and in cultured cell lines. C/EBPb is the substrate of ERK1/2 and/or RPS6KA2 (P90RSK) (16), making C/EBPb a potential mediator of ERK1/2 in GCs. Indeed, when undifferentiated GCs were infected with an adenoviral vector encoding C/EBPb, C/EBPb was expressed, phosphorylated in response to AREG at a known ERK1/2 site and by a MEK1/2dependent mechanism (C/EBPb-T188; Fig. 4A ). Only in C/EBPb-expressing cells could AREG induce ERK1/2-dependent (U0126 sensitive) expression of target genes (Ptgs2, Tnfaip6, Pgr, and Star) ( Fig. 4A and fig. S8A ). AREG and C/EBPb induced the expression of LH/ERK1/2 target genes in Erk1/2 gc−/− GCs only when an ERK2 expression vector restored kinase activity (Fig.  4A) . The synergistic actions of AREG and C/EBPb were compromised dramatically by an ERK1/2 site, but not P90RSK site, point mutation ( fig.  S8A) , indicating that C/EBPb is a direct target of ERK1/2 and both constitute a critical signaling network in preovulatory GCs.
Because the GC-specific functions of C/EBPb have not been studied in vivo, Cebpb fl/fl mice (17) were crossed with the Cyp19-Cre mice, generating the Cebpb fl/fl ;Cyp19-Cre (Cebpb gc−/− ) mouse strain with C/EBPb depleted in GCs ( fig. S7, B to D). As in the Cebpb-null mice (15), the adult Cebpb gc−/− mice were subfertile ( fig. S7E ). CLs were absent in 70% of the adult Cebpb gc−/− mice (n = 10, Fig. 4B ); the number of ovulated COCs was reduced (Fig. 4C) ; and the expression of Ptgs2, Star, and Cyp11a1 was decreased, consistent with impaired CL formation ( fig. S7 , F to G). However, hCG-induced phosphorylation of MEK1/2 and ERK1/2 was normal in ovaries of Cebpb gc−/− mice ( fig. S7D ). Expression of C/EBPb was decreased but not totally blocked in the Erk1/2 gc−/− mice (fig. S8, B and C) , indicating that C/EBPb expression is regulated by additional pathways and that ERK1/2-mediated phosphorylation and activation of C/EBPb is critical. Thus, C/EBPb is a downstream effector of ERK1/2 in GCs during ovulation and luteinization. The lower penetrance of ovulation and gene expression defects in Cebpb gc−/− mice, compared with the Erk1/2 gc−/− mice, suggests that C/EBPb is one, but not the only, critical transcription factor regulated by ERK1/2 in vivo.
The Erk1/2 gc−/− mouse model illustrates that disruption of Erk1/2 in GCs in vivo completely derails the ability of LH to induce genes controlling ovulation, COC expansion, oocyte maturation, and luteinization without altering genes that regulate normal follicular development to the preovulatory stage (summarized in Fig. 4D ). As a consequence of ERK1/2 depletion in GCs, the FSH program is extended rather than being abruptly terminated by LH/hCG. Thus, our results demonstrate in animals that the critical roles of ERK1/2 in GCs are highly selective and cell context-specific, confirming findings of in vitro studies (6, 18) . Moreover, ERK1/2 are activated for a relatively short period of time (from 0.5 to 2 hours) in GCs of the preovulatory follicles exposed to LH/hCG (11, 12, 19) , and this brief window of activation is necessary and suf-ficient to reprogram preovulatory GCs to cease dividing and terminally differentiate.
The effect of ERK1/2 activation in GCs of preovulatory follicles but not in follicles at earlier stages of growth indicates that activation of these kinases is controlled tightly by specific mechanisms. Indeed, inappropriate activation of ERK1/2 in GCs of small growing follicles might disrupt normal follicular development because mice in which ovarian GCs express a constitutively active K-RAS mutant suffer impaired follicle development and premature ovarian failure (11) . Thus, further understanding of the molecular mechanisms by which ERK1/2 regulate ovarian cell functions will help unravel some of the causes of ovarian pathologies and cancer, as well as lead to therapies for female infertility.
